MAPK8 and acute lymphoblastic leukemia: To confirm the therapeutic effect of JNK inhibitor combined with dasatinib on BCR-ABL+ B-ALL in vivo, we tested the efficacy of JNK inhibitor plus dasatinib in the BCR-ABLP190 bone marrow transduction and transplantation mouse model described above.